# Tolerance and Pharmacokinetics With Capecitabine 5 Out of 7 Days Regimen

> **NCT00324610** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie** · enrollment: 46 (—)

## Conditions studied

- Breast Neoplasms
- Chemotherapy

## Interventions

- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT00324610
- **Lead sponsor:** Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 46 (—)
- **Last updated:** 2006-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00324610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00324610, "Tolerance and Pharmacokinetics With Capecitabine 5 Out of 7 Days Regimen". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00324610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*